Cover Image
市場調查報告書

PharmaPoint:黃斑部水腫 (ME) 和黃斑部病變 (MD) - 全球醫藥品市場到2023年前的預測與市場分析

PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325933
出版日期 內容資訊 英文 448 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:黃斑部水腫 (ME) 和黃斑部病變 (MD) - 全球醫藥品市場到2023年前的預測與市場分析 PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023
出版日期: 2014年10月31日 內容資訊: 英文 448 Pages
簡介

黃斑部水腫(ME)是液體積存黃斑的狀態,會引起視力障礙,甚至嚴重到造成失明。老年性黃斑部病變(AMD)是沒有痛覺的眼睛疾病,造成階段性,不可逆的視力低落,是五十歲以上,已開發國家人民的主要失明原因之一。

本報告提供全球黃斑部水腫 (ME) 和黃斑部病變 (MD) 的治療藥市場相關調查分析,提供您疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素·阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 黃斑部病變 (MD) 概要
  • 黃斑部水腫 (ME) 概要

第4章 流行病學 - 黃斑部水腫 (ME)

  • 疾病的背景
  • 危險因素和併發症
  • 全球趨勢
  • 預測手法
  • ME的流行病學預測
  • 議論

第5章 流行病學 - 老年性黃斑部病變 (AMD)

  • 疾病的背景
  • 危險因素和併發症
  • 全球趨勢
  • 預測手法
  • AMD的流行病學預測
  • 議論

第6章 疾病的管理

  • 診斷和治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第7章 競爭評估

  • 概要
  • 產品簡介:領導品牌

第8章 未滿足需求和機會

第9章 開發平台評估

  • 概要
  • 臨床試驗製圖
  • 臨床開發中的潛力藥物
  • 初期開發中的有潛力的藥劑
  • 其他開發中的藥物
  • 生技仿製藥

第10章 現在·未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介

第11章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第12章 附錄

圖表

目錄
Product Code: GDHC111PIDR

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Highlights

Key Questions Answered

  • The ME market has been dominated by anti-VEGF drugs Lucentis and Avastin for many years, however, rival drug Eylea has recently gained approval for ME indications across the 7MM. How will this impact the positions that Lucentis and Avastin hold in this market? How will this change over the forecast period, and which drug will covet the leading position in 2023?
  • The current late stage AMD pipeline is varied, with first-in-class drugs in development for both dry AMD and wet AMD. Which of these will have the biggest impact on the AMD market? What strategies are developers undertaking to penetrate the wet AMD market? Will the novel dry AMD drugs fulfil the huge unmet need for this retinal disease?
  • Population aging is occurring in almost all countries worldwide, particularly in the 7MM. This is expected to have a significant impact on the prevalence of age-related diseases such as AMD and conditions causing ME. How will epidemiological changes impact the growth of the future ME and AMD markets?

Key Findings

  • The main driver of growth in the AMD market will be the introduction of first-in-class drugs over the forecast period. The launch of two new therapies for dry AMD will significantly grow this market and the arrival of adjunctive therapies for wet AMD will further strengthen this growth in the AMD market.
  • The rapid expansion of Eylea within the ME market will lead to a shift in market leader over the forecast period, with Lucentis losing this position to rival anti-VEGF drug Eylea.
  • The biggest barrier for growth in the ME and AMD markets will be the increasing pressure to show drug cost-effectiveness. This is likely to have a negative impact on these markets, as regulatory bodies are adopting stricter criteria for new drug approvals and reimbursement listing.
  • Significant opportunities remain for further drug development in both the ME and AMD markets as numerous unmet needs remain, in particular the need for effective dry AMD drugs with non-invasive formulations.

Scope

  • Overview of ME and AMD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized ME and AMD market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the ME and AMD therapeutics markets.
  • Pipeline analysis: focus on the seven late-stage pipeline ME and AMD drugs discussing emerging trends as well as overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global ME and AMD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global ME and AMD therapeutics markets.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ME and AMD therapeutics markets in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global ME and AMD therapeutics markets from 2013-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Macular Degeneration Overview
    • 3.1.1. Etiology and Pathophysiology
    • 3.1.2. Classification
    • 3.1.3. Symptoms and Diagnosis
  • 3.2. Macular Edema Overview
    • 3.2.1. Etiology and Pathophysiology
    • 3.2.2. Classification
    • 3.2.3. Symptoms and Diagnosis

4. Epidemiology - Macular Edema

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods - Diagnosed Prevalent Cases of Diabetes
    • 4.4.4. Forecast Assumptions and Methods - Diagnosed Prevalent Cases of Diabetic Retinopathy
    • 4.4.5. Forecast Assumptions and Methods - Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population
    • 4.4.6. Forecast Assumptions and Methods - Total Prevalent Cases of ME following BRVO and CRVO
  • 4.5. Epidemiological Forecast for Macular Edema (2013-2023)
    • 4.5.1. Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population
    • 4.5.2. Age-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population
    • 4.5.3. Sex-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population
    • 4.5.4. Total Prevalent Cases of ME Following BRVO
    • 4.5.5. Age-Specific Total Prevalent Cases of ME Following BRVO
    • 4.5.6. Sex-Specific Total Prevalent Cases of ME following BRVO
    • 4.5.7. Total Prevalent Cases of ME Following CRVO
    • 4.5.8. Age-Specific Total Prevalent Cases of ME Following CRVO
    • 4.5.9. Sex-Specific Total Prevalent Cases of ME Following CRVO
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Epidemiology - Age-Related Macular Degeneration

  • 5.1. Disease Background
  • 5.2. Risk Factors and Comorbidities
  • 5.3. Global Trends
    • 5.3.1. US
    • 5.3.2. 5EU
    • 5.3.3. Japan
  • 5.4. Forecast Methodology
    • 5.4.1. Sources Used
    • 5.4.2. Forecast Assumptions and Methods
  • 5.5. Epidemiological Forecast for AMD (2013-2023)
    • 5.5.1. Total Prevalent Cases of AMD
    • 5.5.2. Age-Specific Total Prevalent Cases of AMD
    • 5.5.3. Sex-Specific Total Prevalent Cases of AMD
    • 5.5.4. Age-Standardized Total Prevalence of AMD
    • 5.5.5. Total Prevalent Cases of AMD by Stage
    • 5.5.6. Total Prevalent Cases of Late AMD by Subtype
  • 5.6. Discussion
    • 5.6.1. Epidemiological Forecast Insight
    • 5.6.2. Limitations of the Analysis
    • 5.6.3. Strengths of the Analysis

6. Disease Management

  • 6.1. Diagnosis and Treatment Overview
    • 6.1.1. Macular Edema Diagnosis
    • 6.1.2. Macular Degeneration Diagnosis
    • 6.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 6.1.4. Clinical Practice
  • 6.2. US
  • 6.3. France
  • 6.4. Germany
  • 6.5. Italy
  • 6.6. Spain
  • 6.7. UK
  • 6.8. Japan

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Product Profiles - Major Brands
    • 7.2.1. Lucentis (ranibizumab)
    • 7.2.2. Eylea (aflibercept)
    • 7.2.3. Avastin (bevacizumab)
    • 7.2.4. Macugen (pegaptanib sodium)
    • 7.2.5. Visudyne (verteporfin)
    • 7.2.6. Corticosteroid Implants

8. Unmet Need and Opportunity

  • 8.1. Overview
  • 8.2. Treatment for Dry AMD
    • 8.2.1. Unmet Need
    • 8.2.2. Gap Analysis
    • 8.2.3. Opportunity
  • 8.3. Longer-Acting Anti-VEGF Drug Therapy
    • 8.3.1. Unmet Need
    • 8.3.2. Gap Analysis
    • 8.3.3. Opportunity
  • 8.4. Increased Efficacy of Anti-VEGF Therapy for wAMD
    • 8.4.1. Unmet Need
    • 8.4.2. Gap Analysis
    • 8.4.3. Opportunity
  • 8.5. Less Invasive Drug Formulations
    • 8.5.1. Unmet Need
    • 8.5.2. Gap Analysis
    • 8.5.3. Opportunity
  • 8.6. Awareness and Earlier Patient Diagnosis
    • 8.6.1. Unmet Need
    • 8.6.2. Gap Analysis
    • 8.6.3. Opportunity
  • 8.7. Home Monitoring of AMD Progression
    • 8.7.1. Unmet Need
    • 8.7.2. Gap Analysis
    • 8.7.3. Opportunity

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Clinical Trial Mapping
  • 9.3. Promising Drugs in Clinical Development
    • 9.3.1. Abicipar pegol
    • 9.3.2. Fovista
    • 9.3.3. Squalamine
    • 9.3.4. Lampalizumab
    • 9.3.5. Emixustat
    • 9.3.6. Optina
    • 9.3.7. DE-102
  • 9.4. Promising Drugs in Early-Stage Development
    • 9.4.1. Complement Inhibitors
  • 9.5. Other Drugs in Development
  • 9.6. Biosimilars

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. Roche/Genentech
    • 10.3.2. Novartis
    • 10.3.3. Regeneron
    • 10.3.4. Bayer
    • 10.3.5. Valeant
    • 10.3.6. Allergan
    • 10.3.7. Alimera Sciences
    • 10.3.8. Ampio Pharmaceuticals
    • 10.3.9. Ophthotech
    • 10.3.10. Acucela
    • 10.3.11. Ohr Pharmaceuticals

11. Market Outlook

  • 11.1. Global Markets
    • 11.1.1. Forecast
    • 11.1.2. Drivers and Barriers - Global Issues
  • 11.2. US
    • 11.2.1. Forecast
    • 11.2.2. Key Events
    • 11.2.3. Drivers and Barriers
  • 11.3. France
    • 11.3.1. Forecast
    • 11.3.2. Key Events
    • 11.3.3. Drivers and Barriers
  • 11.4. Germany
    • 11.4.1. Forecast
    • 11.4.2. Key Events
    • 11.4.3. Drivers and Barriers
  • 11.5. Italy
    • 11.5.1. Forecast
    • 11.5.2. Key Events
    • 11.5.3. Drivers and Barriers
  • 11.6. Spain
    • 11.6.1. Forecast
    • 11.6.2. Key Events
    • 11.6.3. Drivers and Barriers
  • 11.7. UK
    • 11.7.1. Forecast
    • 11.7.2. Key Events
    • 11.7.3. Drivers and Barriers
  • 11.8. Japan
    • 11.8.1. Forecast
    • 11.8.2. Key Events
    • 11.8.3. Drivers and Barriers

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Methodology
  • 12.4. Forecasting Methodology
    • 12.4.1. Diagnosed ME and AMD Patients
    • 12.4.2. Percentage of Drug-Treated Patients
    • 12.4.3. Drugs Included in Each Therapeutic Class
    • 12.4.4. Launch and Patent Expiry Dates
    • 12.4.5. General Pricing Assumptions
    • 12.4.6. Individual Drug Assumptions
    • 12.4.7. Pricing of Pipeline Agents
  • 12.5. Primary Research - KOLs Interviewed for this Report
  • 12.6. Primary Research - High-Prescribers Survey
  • 12.7. About the Authors
    • 12.7.1. Analyst
    • 12.7.2. Therapy Area Director
    • 12.7.3. Epidemiologist
    • 12.7.4. Global Head of Healthcare
  • 12.8. About GlobalData
  • 12.9. Disclaimer

List of Tables

  • Table 1: ARM System Classification of AMD
  • Table 2: Symptoms of AMD
  • Table 3: Risk Factors for DME
  • Table 4: Comorbidities for DME
  • Table 5: 7MM, Sources of Diagnosed Prevalence of DME in the Diagnosed Diabetic Retinopathy Population
  • Table 6: 7MM, Sources of Total Prevalence of ME following BRVO and CRVO
  • Table 7: 7MM, Sources Not Used in Epidemiological Analysis of DME
  • Table 8: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Table 9: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Age, Both Sexes, N, (Row %), 2013
  • Table 10: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Sex, Ages ≥20 Years, N (Row %), 2013
  • Table 11: 7MM, Total Prevalent Cases of ME Following BRVO, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Table 12: 7MM, Total Prevalent Cases of ME Following BRVO, by Age, Both Sexes, N, (Row %), 2013
  • Table 13: 7MM, Total Prevalent Cases of ME Following BRVO, by Sex, Ages ≥20 Years, N (Row %), 2013
  • Table 14: 7MM, Total Prevalent Cases of ME Following CRVO, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Table 15: 7MM, Total Prevalent Cases of ME Following CRVO, by Age, Both Sexes, N, (Row %), 2013
  • Table 16: 7MM, Total Prevalent Cases of ME Following CRVO, by Sex, Ages ≥20 Years, N (Row %), 2013
  • Table 17: Risk Factors and Comorbidities for AMD
  • Table 18: Diagnostic Criteria for AMD
  • Table 19: 7MM, Sources of AMD Prevalence Data
  • Table 20: 7MM, Total Prevalent Cases of AMD, Ages ≥50 Years, Both Sexes, N, 2013-2023
  • Table 21: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, (Row %), 2013
  • Table 22: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N (Row %), 2013
  • Table 23: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age ≥50 Years, N (Row %), 2013
  • Table 24: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age ≥50 Years, N (Row %), 2013
  • Table 25: National and International Treatment Guidelines for ME and AMD
  • Table 26: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013
  • Table 27: ME and AMD Disease Management - US
  • Table 28: ME and AMD Disease Management - France
  • Table 29: ME and AMD Disease Management - Germany
  • Table 30: ME and AMD Disease Management - Italy
  • Table 31: ME and AMD Disease Management - Spain
  • Table 32: ME and AMD Disease Management - UK
  • Table 33: ME and AMD Disease Management - Japan
  • Table 34: Leading Treatments for ME and AMD, 2014
  • Table 35: Product Profile - Lucentis
  • Table 36: Lucentis SWOT Analysis, 2014
  • Table 37: Global Sales Forecast ($m) for Lucentis, 2013-2023
  • Table 38: Approval Dates for Eylea
  • Table 39: Product Profile - Eylea
  • Table 40: Eylea - Common Adverse Reactions
  • Table 41: Eylea SWOT Analysis, 2014
  • Table 42: Global Sales Forecast ($m) for Eylea, 2013-2023
  • Table 43: Product Profile - Avastin
  • Table 44: Avastin SWOT Analysis, 2014
  • Table 45: Global Sales Forecast ($m) for Avastin, 2013-2023
  • Table 46: Product Profile - Macugen
  • Table 47: Product Profile - Visudyne
  • Table 48: Visudyne SWOT Analysis, 2014
  • Table 49: Global Sales Forecast ($m) for Visudyne, 2013-2023
  • Table 50: Product Profile - Ozurdex
  • Table 51: Product Profile - Iluvien
  • Table 52: Corticosteroid IVT Implants SWOT Analysis, 2014
  • Table 53: Global Sales Forecast ($m) for Ozurdex, 2013-2023
  • Table 54: Global Sales Forecast ($m) for Iluvien, 2013-2023
  • Table 55: Unmet Needs and Opportunities in ME and AMD
  • Table 56: Promising Drugs in Clinical Development for ME and AMD
  • Table 57: Comparison of Drugs in Development for ME and AMD, 2014
  • Table 58: Product Profile - Abicipar pegol
  • Table 59: SWOT Analysis - Abicipar pegol, 2014
  • Table 60: Global Sales Forecast ($m) for Abicipar Pegol, 2013-2023
  • Table 61: Product Profile - Fovista
  • Table 62: SWOT Analysis - Fovista, 2014
  • Table 63: Global Sales Forecast ($m) for Fovista, 2013-2023
  • Table 64: Product Profile - Squalamine
  • Table 65: SWOT Analysis - Squalamine, 2014
  • Table 66: Global Sales Forecast ($m) for squalamine, 2013-2023
  • Table 67: Product Profile - Lampalizumab
  • Table 68: SWOT Analysis - Lampalizumab, 2014
  • Table 69: Global Sales Forecast ($m) for lampalizumab, 2013-2023
  • Table 70: Product Profile - Emixustat
  • Table 71: SWOT Analysis - Emixustat, 2014
  • Table 72: Global Sales Forecast ($m) for emixustat, 2013-2023
  • Table 73: Product Profile - Optina
  • Table 74: SWOT Analysis - Optina, 2014
  • Table 75: Global Sales Forecast ($m) for Optina, 2013-2023
  • Table 76: Product Profile - DE-102
  • Table 77: DE-102 SWOT Analysis, 2014
  • Table 78: Global Sales Forecast ($m) for DE-102, 2013-2023
  • Table 79: Early-Stage Drugs in Clinical Development for ME and AMD, 2014
  • Table 80: Key Companies in the ME and AMD Markets in the 7MM, 2014
  • Table 81: Roche/Genentech's ME and AMD Portfolio Assessment, 2014
  • Table 82: Novartis' ME and AMD Portfolio Assessment, 2014
  • Table 83: Regeneron's ME and AMD Portfolio Assessment, 2014
  • Table 84: Bayer's ME and AMD Portfolio Assessment, 2014
  • Table 85: Valeant's AMD Portfolio Assessment, 2014
  • Table 86: Allergan's ME and AMD Portfolio Assessment, 2014
  • Table 87: Alimera Sciences' ME Portfolio Assessment, 2014
  • Table 88: Ampio's ME Portfolio Assessment, 2014
  • Table 89: Ophthotech's AMD Portfolio Assessment, 2014
  • Table 90: Acucela's AMD Portfolio Assessment, 2014
  • Table 91: Ohr Pharmaceutical's AMD Portfolio Assessment, 2014
  • Table 92: Global Sales Forecast ($m) for ME, 2013-2023
  • Table 93: Global Sales Forecast ($m) for AMD, 2013-2023
  • Table 94: ME and AMD Markets - Drivers and Barriers, 2013-2023
  • Table 95: Sales Forecast ($m) for ME in the U, 2013-2023
  • Table 96: Sales Forecast ($m) for AMD in the United States, 2013-2023
  • Table 97: Key Events Impacting Sales for ME and AMD in the US, 2013-2023
  • Table 98: ME and AMD Markets - Drivers and Barriers in the US, 2013-2023
  • Table 99: Sales Forecast ($m) for ME in France, 2013-2023
  • Table 100: Sales Forecast ($m) for AMD in France, 2013-2023
  • Table 101: Key Events Impacting Sales for ME and AMD in France, 2013-2023
  • Table 102: ME and AMD Markets - Drivers and Barriers in France, 2013-2023
  • Table 103: Sales Forecast ($m) for ME in Germany, 2013-2023
  • Table 104: Sales Forecast ($m) for AMD in Germany, 2013-2023
  • Table 105: Key Events Impacting Sales for ME and AMD in Germany, 2013-2023
  • Table 106: ME and AMD Markets - Drivers and Barriers in Germany, 2013-2023
  • Table 107: Sales Forecast ($m) for ME in Italy, 2013-2023
  • Table 108: Sales Forecast ($m) for AMD in Italy, 2013-2023
  • Table 109: Key Events Impacting Sales for MME and AMD in Italy, 2013-2023
  • Table 110: ME and AMD Markets - Drivers and Barriers in Italy, 2013-2023
  • Table 111: Sales Forecast ($m) for ME in Spain, 2013-2023
  • Table 112: Sales Forecast ($m) for AMD in Spain, 2013-2023
  • Table 113: Key Events Impacting Sales for ME and AMD in Spain, 2013-2023
  • Table 114: ME and AMD Markets - Drivers and Barriers in Spain, 2013-2023
  • Table 115: Sales Forecast ($m) for ME in the UK, 2013-2023
  • Table 116: Sales Forecast ($m) for AMD in the UK, 2013-2023
  • Table 117: Key Events Impacting Sales for ME and AMD in the UK, 2013-2023
  • Table 118: ME and AMD Markets - Drivers and Barriers in the UK, 2013-2023
  • Table 119: Sales Forecast ($m) for ME in Japan, 2013-2023
  • Table 120: Sales Forecast ($m) for AMD in Japan, 2013-2023
  • Table 121: Key Events Impacting Sales for ME and AMD in Japan, 2013-2023
  • Table 122: ME and AMD Markets - Drivers and Barriers in Japan, 2013-2023
  • Table 123: Key Launch Dates
  • Table 124: Key Patent Expiries
  • Table 125: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Anatomy of the Eye and Macula
  • Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
  • Figure 3: Color Fundus Photographs of Dry and Wet AMD
  • Figure 4: FAF Imaging of GA
  • Figure 5: Imaging of wAMD
  • Figure 6: CMT in DME
  • Figure 7: RVOs (BRVO and CRVO) on an FA
  • Figure 8: Increased CRT in ME-RVO
  • Figure 9: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Figure 10: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Age, Both Sexes, N, 2013
  • Figure 11: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Sex, Ages ≥20 Years, N, 2013
  • Figure 12: 7MM, Total Prevalent Cases of ME Following BRVO, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Figure 13: 7MM, Total Prevalent Cases of ME Following BRVO, by Age, Both Sexes, N, 2013
  • Figure 14: 7MM, Total Prevalent Cases of ME Following BRVO, by Sex, Ages ≥20 Years, N, 2013
  • Figure 15: 7MM, Total Prevalent Cases of ME Following CRVO, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Figure 16: 7MM, Total Prevalent Cases of ME Following CRVO, by Age, Both Sexes, N, 2013
  • Figure 17: 7MM, Total Prevalent Cases of ME Following CRVO, by Sex, Ages ≥20 Years, N, 2013
  • Figure 18: 7MM, Total Prevalent Cases of AMD, Ages ≥50 Years, Both Sexes, N, 2013-2023
  • Figure 19: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, 2013
  • Figure 20: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N, 2013
  • Figure 21: 7MM, Age-Standardized Total Prevalence (%) of AMD, Age ≥50 Years, by Sex, 2013
  • Figure 22: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age ≥50 Years, N, 2013
  • Figure 23: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age ≥50 Years, N, 2013
  • Figure 24: ME Clinical Treatment Flowchart
  • Figure 25: AMD Clinical Treatment Flowchart
  • Figure 26: Eylea's Clinical Development in DME and ME-BRVO
  • Figure 27: Iluvien's and Ozurdex's Clinical Development in wAMD, dAMD, and DME
  • Figure 28: ME and AMD therapeutics - Number of Phase II and III Clinical Trials in Each Indication in the 7MM
  • Figure 29: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023
  • Figure 30: Abicipar Pegol's Clinical Development in wAMD and DME
  • Figure 31: Clinical and Commercial Positioning of abicipar pegol
  • Figure 32: Fovista's Clinical Development in wAMD
  • Figure 33: Clinical and Commercial Positioning of Fovista
  • Figure 34: Squalamine's Clinical Development in wAMD and DME
  • Figure 35: Clinical and Commercial Positioning of squalamine
  • Figure 36: Lampalizumab's Development in wAMD
  • Figure 37: Clinical and Commercial Positioning of lampalizumab
  • Figure 38: Emixustat Clinical Development in dAMD
  • Figure 39: Clinical and Commercial Positioning of emixustat
  • Figure 40: Optina's Clinical Development in DME
  • Figure 41: Clinical and Commercial Positioning of Optina
  • Figure 42: DE-102's Clinical Development in DME and ME-BRVO
  • Figure 43: Clinical and Commercial Positioning of DE-102
  • Figure 44: Global Sales of Branded Products for ME and AMD by Company, 2013-2023
  • Figure 45: Company Portfolio Gap Analysis in ME and AMD, 2013-2023
  • Figure 46: Roche/Genentech's SWOT Analysis in ME and AMD, 2013-2023
  • Figure 47: Novartis' SWOT Analysis in ME and AMD, 2013-2023
  • Figure 48: Regeneron's SWOT Analysis in ME and AMD, 2013-2023
  • Figure 49: Bayer's SWOT Analysis in ME and AMD, 2013-2023
  • Figure 50: Valeant's SWOT Analysis in AMD, 2013-2023
  • Figure 51: Allergan's SWOT Analysis in ME and AMD, 2013-2023
  • Figure 52: Alimera Sciences' SWOT Analysis in ME, 2013-2023
  • Figure 53: Ampio's SWOT Analysis in ME, 2013-2023
  • Figure 54: Ophthotech's SWOT Analysis in AMD, 2013-2023
  • Figure 55: Acucela's SWOT Analysis in AMD, 2013-2023
  • Figure 56: Ohr Pharmaceutical's SWOT Analysis in AMD, 2013-2023
  • Figure 57: Global Sales for ME by Region, 2013-2023
  • Figure 58: Individual Drug Sales for ME 2013-2023
  • Figure 59: Global Sales for AMD by Region, 2013-2023
  • Figure 60: Individual Drug Sales for AMD 2013-2023
  • Figure 61: Individual Drug Sales for ME in the US, 2013-2023
  • Figure 62: Individual Drug Sales for AMD in the US, 2013-2023
  • Figure 63: Individual Drug Sales for ME in France, 2013-2023
  • Figure 64: Individual Drug Sales for AMD in France, 2013-2023
  • Figure 65: Individual Drug Sales for ME in Germany, 2013-2023
  • Figure 66: Individual Drug Sales for AMD in Germany, 2013-2023
  • Figure 67: Individual Drug Sales for ME in Italy, 2013-2023
  • Figure 68: Individual Drug Sales for AMD in Italy, 2013-2023
  • Figure 69: Individual Drug Sales for ME in Spain, 2013-2023
  • Figure 70: Individual Drug Sales for AMD in Spain, 2013-2023
  • Figure 71: Individual Drug Sales for ME in the UK, 2013-2023
  • Figure 72: Individual Drug Sales for AMD in the UK, 2013-2023
  • Figure 73: Individual Drug Sales for ME in Japan, 2013-2023
  • Figure 74: Individual Drug Sales for AMD in Japan, 2013-2023
Back to Top